The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| SLS | +286.79% | -38.9% | -9.38% | -99% |
| S&P | +16.22% | +82.58% | +12.79% | +158% |
SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S and nelipepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.
No news articles found for Sellas Life Sciences Group.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00K | 0.0% |
| Gross Profit | $0.00K | 0.0% |
| Market Cap | $169.53M | 110.8% |
| Market Cap / Employee | $11.30M | 0.0% |
| Employees | 15 | 0.0% |
| Net Income | -$6,791.00K | 4.5% |
| EBITDA | -$7,083.00K | 3.4% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $44.42M | 110.2% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00K | 0.0% |
| Short Term Debt | $599.00K | 4.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -66.47% | 120.2% |
| Return On Invested Capital | -146.57% | 1.9% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$7,068.00K | 9.5% |
| Operating Free Cash Flow | -$7,068.00K | 9.5% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 4.21 | 8.44 | 7.17 | 6.18 | -75.06% |
| Price to Tangible Book Value | 4.79 | 10.58 | 7.70 | 6.67 | -90.77% |
| Enterprise Value to EBITDA | -9.24 | -11.08 | -27.82 | -18.45 | 108.82% |
| Return on Equity | -4147.9% | -144.9% | -180.7% | -84.3% | -84.24% |
| Total Debt | $1.00M | $870.00K | $737.00K | $599.00K | 3.99% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
